Buparlisib

Generic Name: Buparlisib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁F_₃N_₆O_₂

CAS Number: 944396-07-0

Unique Ingredient Identifier: 0ZM2Z182GD

Background: Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Will Adlai Be The First To Deliver A PI3K Inhibitor For Head And Neck Squamous Cell Carcinoma?

Adlai Nortye (ANL) is developing Buparlisib, a PI3K inhibitor for recurrent/metastatic HNSCC post-anti-PD(L)1 treatment, with a phase III trial (BURAN) underway. Expected OS data in Q1 2025. ANL also has two other clinical drugs, AN4005 and AN0025, and a cash position of $98M as of June 2024.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy